Project Type: Clinical Trial
Open: recruiting until 30 September 2024
About the project: The trial will look at the use of a drug called Memantine for treatment of people with Parkinson’s with dementia (PDD) symptoms or Dementia with Lewy Bodies (DLB).
The aim of the trial is to find out if adding Memantine treatment can help improve overall health and functioning for people who are already taking a cholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine).
What’s involved?: If you agree to take part, you will join one of two trial treatment groups for 12 months: a placebo (‘dummy’ drug) group OR a medication (Memantine) group.
You will have planned visits and phone calls with the Neuroprogressive and Dementia Clinical Research team, who will ask you about your symptoms, how you feel and your study treatment. A family member or person who knows you well will also be asked to answer questions about your symptoms and about how they are feeling.
The study visits will be conducted at the Clinical Research Facility at the Western General Hospital and taxi transport can be organised.
Who is eligible to take part?: To take part in the trial, you will be aged over 55 years and have been taking an acetylcholinesterase inhibitor medication such as Donepezil, Rivastigmine or Galantamine for at least 12 weeks.
For more information: Please contact the Neuroprogressive and Dementia Network Clinical Research team:
Maria Dewar, Jess Crossan or Gordon Duncan
Email: loth.sdcrn@nhs.scot
Tel: 0131 537 3804
Website
https://research.ncl.ac.uk/cobalttrial/